Ovid Therapeutics Inc.
Use of MIR-92A or MIR-145 in the treatment of Angelman syndrome
Last updated:
Abstract:
Expression of micoRNAs that negatively regulate the activity of the SNHG14 gene for can be used in treatment of Angelman Syndrome. Such microRNAs include, for example, MIR-92a and/or MIR-145, as well as analogues and variants thereof, for use in treatment of Angelman Syndrome. Expression vectors such as, for example, AAV vectors may be used to transduce cells for introduction of MIR-92a and/or MIR-145 into target tissues for treatment of Angelman Syndrome.
Status:
Grant
Type:
Utility
Filling date:
7 Jul 2020
Issue date:
28 Sep 2021